Aptevo Therapeutics (APVO) Total Current Liabilities (2016 - 2023)
Historic Total Current Liabilities for Aptevo Therapeutics (APVO) over the last 9 years, with Q3 2023 value amounting to $6.8 million.
- Aptevo Therapeutics' Total Current Liabilities fell 1220.14% to $6.8 million in Q3 2023 from the same period last year, while for Sep 2023 it was $6.8 million, marking a year-over-year decrease of 1220.14%. This contributed to the annual value of $8.7 million for FY2022, which is 7495.18% down from last year.
- Per Aptevo Therapeutics' latest filing, its Total Current Liabilities stood at $6.8 million for Q3 2023, which was down 1220.14% from $6.9 million recorded in Q2 2023.
- Aptevo Therapeutics' 5-year Total Current Liabilities high stood at $38.2 million for Q4 2019, and its period low was $5.8 million during Q1 2023.
- For the 5-year period, Aptevo Therapeutics' Total Current Liabilities averaged around $17.9 million, with its median value being $14.5 million (2020).
- In the last 5 years, Aptevo Therapeutics' Total Current Liabilities plummeted by 8008.97% in 2020 and then skyrocketed by 34078.83% in 2021.
- Over the past 5 years, Aptevo Therapeutics' Total Current Liabilities (Quarter) stood at $38.2 million in 2019, then crashed by 61.98% to $14.5 million in 2020, then surged by 139.06% to $34.8 million in 2021, then crashed by 74.95% to $8.7 million in 2022, then decreased by 21.48% to $6.8 million in 2023.
- Its last three reported values are $6.8 million in Q3 2023, $6.9 million for Q2 2023, and $5.8 million during Q1 2023.